Diphenhydramine

Generic Name: Diphenhydramine

Brand Names: Acetadryl, Advil PM, Aleve PM, Allegra Cooling Relief Anti-itch, Banophen, Benadryl, Benadryl Itch Stopping, Benadryl-D Allergy and Sinus, Calagel, Damylin With Codeine, Dimetapp Nighttime Cold & Congestion, Diphen, Diphenhist, Diphenist, Excedrin PM Triple Action, Goody's PM, Legatrin PM, Motrin PM, Nytol, Nytol Quickgels, Percogesic Reformulated Jan 2011, Siladryl, Simply Sleep, Sleepinal, Sominex, Triaminic Night Time Cold & Cough, Tylenol PM, Unisom, Unisom Sleep, Vanamine, Wal-dryl, Wal-som (doxylamine), Zzzquil

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₁NO

CAS Number: 58-73-1

Unique Ingredient Identifier: 8GTS82S83M

Background: Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes . However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties . As histamine receptors exist both ...

Indication: Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insom...

Associated Conditions: Allergic Reaction, Allergic Rhinitis (AR), Allergic cough, Allergy to Tree Pollen, Anaphylaxis, Angioedema, Common Cold, Conjunctival irritation, Cough, Cough Variant Asthma, Cough caused by Common Cold, Eye allergy, Fever, Insect Bites, Insect Stings, Insomnia, Irritative cough, Itching of the nose, Itching of the throat, Motion Sickness, Nasal Congestion, Oral Mucositis, Pain, Parkinsonian Syndromes, Productive cough, Pruritus, Rash, Rhinorrhoea, Sinus Congestion, Sinus headache, Skin Irritation, Sneezing, Sunburn, Symptoms of Acute Bronchitis Accompanied by Coughing, Upper respiratory tract hypersensitivity reaction, site unspecified, Urticaria, Cold or flu syndrome, Dermatographism, Dry cough, Watery itchy eyes

Associated Therapies: Airway secretion clearance therapy, Expectorant

Clinical Trials

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Phase 3

Not yet recruiting

Conditions: Advanced and Metastatic NSCLC

Interventions: Drug: Diphenhydramine
Drug: Tislelizumab
Drug: Pemetrexed
Drug: Albumin paclitaxel
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2024-11-26

Last Posted Date: 2024-12-16

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 430

Registration Number: NCT06704620

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 2

Not yet recruiting

Conditions: Plasma Cell Myeloma Refractory

Interventions: Drug: Isatuximab SC-OBDS
Drug: Montelukast
Drug: Dexamethasone
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Methylprednisolone
Drug: Carfilzomib

First Posted Date: 2024-04-10

Last Posted Date: 2024-11-22

Lead Sponsor: Sanofi

Target Recruit Count: 64

Registration Number: NCT06356571

Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness

Phase 4

Completed

Conditions: Acute Mountain Sickness
AMS

Interventions: Other: Immediate descent from altitude.
Drug: Diphenhydramine
Drug: Prochlorperazine 10 mg

First Posted Date: 2024-03-15

Last Posted Date: 2024-05-28

Lead Sponsor: CHRISTUS Health

Target Recruit Count: 30

Registration Number: NCT06310642

Locations: 🇺🇸
CHRISTUS Health-Texas A&M Spohn Emergency Medicine Residency, Corpus Christi, Texas, United States

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Phase 1

Recruiting

Conditions: Metastatic Appendiceal Adenocarcinoma
Intraperitoneal Paclitaxel

Interventions: Drug: Dexamethasone
Drug: Diphenhydramine
Drug: Famotidine
Drug: Paclitaxel

First Posted Date: 2024-01-16

Last Posted Date: 2024-07-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT06207305

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Intravenous Fluids in Pediatric Migraine

Not Applicable

Recruiting

Conditions: Migraine in Children
Migraine

Interventions: Other: 1/2 maintenance fluids
Drug: Ketorolac
Drug: Diphenhydramine
Other: bolus
Drug: Prochlorperazine

First Posted Date: 2023-12-26

Last Posted Date: 2023-12-26

Lead Sponsor: Dayton Children's Hospital

Target Recruit Count: 134

Registration Number: NCT06182098

Locations: 🇺🇸
Dayton Children's Hosptial, Dayton, Ohio, United States

Intranasal Ketorolac Trial

Phase 2

Recruiting

Conditions: Headache, Migraine

Interventions: Drug: Ketorolac
Drug: Prochlorperazine
Drug: Diphenhydramine

First Posted Date: 2023-10-16

Last Posted Date: 2024-07-24

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 120

Registration Number: NCT06083571

Locations: 🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination with Radiotherapy (RT) in Relapsed/refractory Follicular Lymphoma

Phase 2

Recruiting

Conditions: Follicular Lymphoma

Interventions: Drug: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine phosphate
Drug: Prednisone
Drug: Diphenhydramine
Drug: Acetaminophen

First Posted Date: 2023-09-21

Last Posted Date: 2024-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT06043323

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

Phase 4

Recruiting

Conditions: Fabry's Disease

Interventions: Drug: AGALSIDASE BETA (GZ419828)
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Dexamethasone
Drug: Montelukast

First Posted Date: 2023-08-31

Last Posted Date: 2024-08-09

Lead Sponsor: Sanofi

Target Recruit Count: 18

Registration Number: NCT06019728

Locations: 🇺🇸
Emory University School of Medicine Site Number : 1005, Atlanta, Georgia, United States
🇺🇸
Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 1002, Fairfax, Virginia, United States
🇺🇸
Infusion Associates Site Number : 1001, Grand Rapids, Michigan, United States

and more 2 locations